title: [Disinfectants for the skin of premature].
abstract: Nosocomial infections are among the leading causes of mortality and morbidity in neonatal intensive care units. Prevention of healthcare-associated infections is based on strategies that aim to limit susceptibility to infections by enhancing host defences, interrupting trasmission of organisms by healthcare workers and by promoting the judicious use of antimicrobials. Strategies for the prevention of nosocomial infections include hand hygiene practices, prevention of central venous (cvc)-related bloodstream infections, judicious use of antimicrobials for therapy, enhancement of host defences, skin care and early enteral feeding with human milk. Major concerns about the use of alcoholic chlorhexidine are for the high risk of skin burns in extremely premature infants during the first days of life, when the skin is thin and not fully keratinesed. Aqueous chlorhexidine could be less irritant when used in very low birthweigth infants and thus could represent a good option. A recent prospective trial of adult patients showed similar effectiveness of alcoholic and aqueos solutions of chlorexidine. However, to date no study evaluated whether the aqueos formulation is less harmful and as effective as the alcoholic formulation in neonatal infants. The lack of evidence for neonatal patients prompts urgent need for large randomised controlled trials comparing effectiveness and safety of different skin disinfectants before CVC placement in neonates and particulary in very low birth-weight infants. Nosocomial infections are still of the most serious problems for the neonatal intensive care unit. Therefore every effort must be implemented to reduce the incidence of these infections, can not be considered a toll required hospitalization, as it may not be acceptable for a place of shelter and care as the hospital may itself be a source of disease.
authors.affiliation: Struttura Complessa di Patologia Neonatale, Terapia Intensiva e Neonatologia, Fondazione I.R.C.C.S. Policlinico S. Matteo, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cucurachi
authors.forename: M G
authors.initials: MG
authors.lastname: Tuoto
mesh_terms: D000328:Adult; D000438:Alcohols; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000517:prevention & control*; D055499:Catheter-Related Infections / Q000517:prevention & control; D002710:Chlorhexidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000075202:Contraindications; D003428:Cross Infection / Q000453:epidemiology / Q000517:prevention & control*; D006235:Hand Disinfection; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D015994:Incidence; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000453:epidemiology / Q000517:prevention & control*; D019102:Infant, Very Low Birth Weight; D017053:Infection Control / Q000379:methods*; D017757:Infectious Disease Transmission, Professional-to-Patient / Q000517:prevention & control; D015931:Intensive Care, Neonatal / Q000379:methods*; D011206:Povidone-Iodine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000382:microbiology*; D012869:Skin Absorption; D012997:Solvents; D014867:Water
chemical_list: D000438:Alcohols; D000891:Anti-Infective Agents, Local; D012997:Solvents; D014867:Water; D011206:Povidone-Iodine; C010882:chlorhexidine gluconate; D002710:Chlorhexidine